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Variants in RBP4 and AR genes modulate age at onset
in familial amyloid polyneuropathy (FAP ATTRV30M)
Diana Santos1,2, Teresa Coelho3, Miguel Alves-Ferreira1,2, Jorge Sequeiros1,2, Denisa Mendonça2,4,
Isabel Alonso1,2, Carolina Lemos*,1,2 and Alda Sousa1,2
Familial amyloid polyneuropathy (FAP) ATTRV30M is a neurodegenerative disorder due to point mutations in the transthyretin
gene, with V30M being the commonest. FAP ATTRV30M shows a wide variation in age at onset (AO) between clusters, families
and generations. Portuguese patients also show remarkable AO differences between genders. Genes found to be associated with
FAP ATTRV30M pathways may act as AO modiﬁers. Our aim was to further explore the role of APCS and RBP4 genes and to
study for the ﬁrst time the involvement of sex-linked genetic modiﬁers – AR and HSD17B1 genes – in AO variation in
Portuguese families. We collected DNA from a sample of 318 patients, currently under follow-up. A total of 18 tagging SNPs
from APCS, RBP4, AR and HSD17B1 and 5 additional SNPs from APCS and RBP4 previously studied were genotyped. To
account for nonindependency of AO between members of the same family, we used generalized estimating equations (GEEs). We
found that APCS and RBP4 were associated with late AO. In addition, rs11187545 of the RBP4 was associated with an early
AO. For the AR, in the male group three SNPs were associated with an early AO, whereas in the female group four were
associated with both an early and later AO. These results strengthened the role of APCS and RBP4 genes and revealed for the
ﬁrst time the contribution of AR genes as an AO modiﬁer in both males and females. These ﬁndings may have important
implications in genetic counseling and for new therapeutic strategies.
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INTRODUCTION
Familial amyloid polyneuropathy (FAP) ATTRV30M is an autosomal
dominant systemic amyloidosis characterized by amyloid deposition of
mutated ﬁbrillar transthyretin (TTR) protein. The main clinical
expression of this disease is a progressive peripheral sensorimotor
and autonomic neuropathy due to a point mutation in the TTR gene
(chr18q12.1) (OMIM 176300). Although more than 100 mutations
have been found in the TTR gene,1 V30M, NM_000371.3:c.148G4A
(p.(Val50Met)) is the commonest.
Andrade2 ﬁrst described FAP in Northern Portugal as a disease
occurring between 25 and 35 years. Variation in age at onset (AO)
between clusters and within the same focus has been described.3–6
Among Portuguese families, a remarkable wide variation in AO (19–
82 years) has been observed, and an increasing number of late-onset
cases (≥50 years) are being ascertained, including asymptomatic
carriers aged 95 years.4
Variation in AO between generations has also been observed: late-
onset parents often have early-onset offspring (o40 years) – an
evidence for anticipation – whereas the reverse has never been
observed. Recently, our group has shown that anticipation is a true
biological phenomenon in FAP ATTRV30M.6
In order to clarify why there is such a striking AO variation in FAP
ATTRV30M, an attractive strategy is to focus on modiﬁer genes that
can affect transcription through immediate gene transcript expression
or translate into phenotypical alterations at multiple organizational
levels.7 Some modiﬁer genes such as amyloid P component, serum
(APCS), complement C1QA and C1QC and plasma retinol-binding
protein 4 (RBP4) have been unraveled so far but they only explain a
small part of the AO variability in FAP ATTRV30M.8,9 In a previous
study, Soares et al9 compared Portuguese patients in a classic case–
control approach; these authors found that the variants studied in the
APCS gene had a combined modiﬁer effect when analyzing early-onset
group versus controls, whereas the combination of one variant from
APCS (rs6689429) and two variants from RBP4 (rs7091052 and
rs28383574) seemed to be involved with late-onset group.9 No
comparisons were made between early- and late-onset cases.
The APCS gene encodes a highly conserved plasma glycoprotein
that is associated with amyloid deposition independently of protein
origin. Apart from the plasma, APCS can also exist in amyloid
deposits10 and has the ability to bind to several ligands such as amyloid
ﬁbrils through a speciﬁc calcium-dependent mechanism.10 In humans,
the biological role of this protein has yet to be clariﬁed. However,
recently, it was found that the APCS has become an attractive
therapeutic target in amyloid diseases.11
RBP4 gene encodes the speciﬁc carrier of retinol in the human
plasma. RBP4 is synthesized in the liver and when binding to all-trans-
retinol circulates as a complex with TTR, forming a ternary
RBP4–retinol–TTR complex. In the blood, the formation of the
RBP4–retinol–TTR complex causes the apparent increase of molecular
mass and thus prevents its loss through glomerular ﬁltration by the
kidneys, stabilizing the quaternary structure of TTR.12
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In several studies with Portuguese FAP ATTRV30M patients, women
were found to have later onset than men.4,13 Our group recently
reiterated this ﬁnding.6 Moreover, mother–son pairs showed larger
anticipation whereas the father–daughter pairs showed only residual
anticipation.6 Therefore, to clarify gender-related differences associated
with AO variation we will focus on sex steroid hormones as androgen
receptor (AR) and hydroxysteroid (17-β) dehydrogenase 1 (HSD17B1).
Both affect TTR expression levels, but AR seems to have a stronger
inducer effect in the TTR expression than HSD17B1.14 The AR gene is
located in the X chromosome and its nuclear transcription factor is
activated to mediate binding of the androgenic hormones testosterone
and 5α-dihydrotestosterone, whereas the HSD17B1 gene may play an
important role in regulating the local cellular levels of estradiol.15
Therefore, the aim of this study was to investigate whether variants
of these candidate genes have a modiﬁer effect in AO within FAP
ATTRV30M families, what was not taken into account in previous
studies.
We reassessed the role of APCS and RBP4 genes and for the ﬁrst




Unidade Corino de Andrade (UCA-CHP, Porto, Portugal) has the largest FAP
ATTRV30M registry worldwide: over 2000 patients, belonging to more than
500 families, collected over 75 years and clinically well characterized. We
concentrated on families with at least two generations affected and currently
under follow-up at CHP. We achieved a sample of 318 patients from 106
families, coming from different geographical areas of the country.
For each individual, AO had been established by the same team of
neurologists specialized in FAP ATTRV30M when the ﬁrst sensorimotor
symptoms were observed. The DNA samples of these patients were collected
and stored at the Centro de Genética Preditiva e Preventiva (CGPP, Porto,
Portugal) biobank, authorized by CNPD (National Commission for Data
Protection).
All patients gave written informed consent and the study was approved by
the Ethics Committee of CHP.
DNA extraction
Genomic DNA was extracted from peripheral blood leukocytes using the
standard salting-out method16 or from saliva using ORAGENE kits according
to the manufacturer’s instructions (DNA Genotek, Inc., Kanata, ON, Canada).
Selection of SNPs and genotyping
We selected a total of 18 tagging single-nucleotide polymorphisms (SNPs)
(Supplementary Table 1) through the degree of linkage disequilibrium (LD)
existing between them, using Haploview v.4.1,17 at an r2 threshold of 0.80 (with
a minor allele frequency of 0.10%). We also included ﬁve SNPs previously
studied in order to replicate the results found by Soares et al.9
The SNP frequencies in the European population were obtained by resorting
to the HapMap Project and dbSNP. All variants were submitted to the Leiden
Open Variation Database shared installation (URL: http://databases.lovd.nl/
shared/screenings?search_owned_by_=="Carolina%20Lemos"), with the fol-
lowing submission IDs: APCS: http://www.lovd.nl/APCS; AR: http://www.
lovd.nl/AR; HSD17B1: http://www.lovd.nl/HSD17B1; RBP4: http://www.lovd.
nl/RBP4 (patient IDs 38827–39346).
Primers were designed using Primer3Plus software (http://www.bioinfor
matics.nl/cgi-bin/primer3plus/primer3plus.cgi). Afterwards, the AutoDimer
software (http://www.cstl.nist.gov/strbase/AutoDimerHomepage/AutoDimer
ProgramHomepage.htm) was used to assess the formation of hairpins and
primer–dimer secondary structures. Single base extension (SBE) primers were
designed as described in the literature.18
A multiplex reaction for 18 tagging SNPs was carried out using the QIAGEN
Multiplex PCR Kit (Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. Ampliﬁed products were puriﬁed with ExoSAP-IT (Amersham
Biosciences, Uppsala, Sweden). Genotyping was performed by a SNaPshot
reaction using the SNaPshot Multiplex kit (Applied Biosystems, Foster City,
CA, USA). Final products were puriﬁed with SAP (Amersham Biosciences).
To genotype rs6689429, rs3758539, rs28383574 and rs7091052, PCR
products were digested using BsaJI, MnlI, BsrI and HinP1I restriction enzymes
and loaded in QIAxcel multicapillary electrophoresis system (Qiagen). For
rs28383573, genotyping was performed by sequencing. In addition, uncertain
genotypes were sequenced. Automatic sequencing was performed using the Big
Dye Terminator Cycle Sequencing v1.1, Ready Reaction (Applied Biosystems)
according to the manufacturer’s instructions. Samples resulting from the
SNaPshot reaction and sequencing were loaded in an ABI-PRISM 3130 XL
Genetic Analyzer (Applied Biosystems). SNaPshot results were analyzed with
the GeneMapper v4.0 software (Foster City, CA, USA).
Design and statistical analysis
Our family-centered approach means that we included in the analysis several
members of the same family, and therefore each patient was ‘nested’ in his/her
family. To account for nonindependency of AO between members of the same
family, we used generalized estimating equations (GEEs).19
Therefore, we assessed any simultaneous association of the different variants
with AO in FAP ATTRV30M (as the dependent variable) using the most
common genotype as the reference category.
The unstandardized coefﬁcient (B) corresponds to the mean AO variation
observed in the individuals carrying a speciﬁc genotype when compared with
the reference category. To correct for multiple testing, we applied a Bonferroni
correction. All statistical analyses were performed using IBM SPSS Statistics
software (v.20; Armonk, NY, USA).
Haplotypes estimation was performed using SNPator software.20 To estimate
haplotype frequencies, the Haploview v.4.1 software was also used. Parental
transmission was assessed using Fisher’s exact test.
To detect gene–gene interactions, we used Multifactor Dimensionality
Reduction (MDR) software (v.2.0).21 Signiﬁcant results were corrected for
multiple testing, based on a 1000-fold permutation test, using the MDR
Permutation Testing Module (v.1.0).
SNP Function Prediction (FuncPred), a bioinformatic tool, was used to
predict putative SNP functional effects.22
RESULTS
Our patient sample shows a mean AO of ∼ 39 years; however, mean
AO in males (37.28) is lower than in females (40.52), as already
described in the literature4,6 (Table 1).
Using a candidate-gene approach with 318 Portuguese FAP
ATTRV30M patients, we unraveled some variants for the ﬁrst time
associated with AO variation in FAP ATTRV30M, as presented in
Table 2.
The role of APCS gene
Regarding the genotype GT for the rs28383573, we did not ﬁnd a
signiﬁcant result. However, it is worth noting that one individual with
the TT genotype presented a later onset and the difference corre-
sponds to an increase of 26 years in mean AO (Table 2). For the other
SNPs assessed, no signiﬁcant results were found.
Table 1 Mean AO of male and female patients
Gender N Range Minimum Maximum Mean AO SD
AO
Male 152 51 21 72 37.28 13.96
Female 166 53 21 74 40.52 12.30
Total 318 53 21 74 38.97 13.19
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RBP4 gene and AO
We found that the CC genotype (P= 0.012) and the CT genotype
(P= 0.011) of rs7094671 were associated with a later onset (increasing
AO in 19 and 10 years, respectively). The CT genotype (P= 0.035) of
rs11187545 was associated with an earlier onset when compared with
the TT genotype, with a decrease of 9 years in AO (although this is the
only result that does not stand after multiple testing correction).
Noteworthy, the individual with the CC genotype also presented an
earlier onset.
Using MDR, we analyzed a possible interaction between APCS and
RBP4 genes but we did not ﬁnd any strong interaction (data not
shown).
The involvement of sex hormone genes
Taking into account that AR gene is located in the X chromosome the
analyses were stratiﬁed by gender and the genotypic analyses were only
performed in the female group. We found a total of ﬁve SNPs
signiﬁcantly associated with AO variation in the AR gene, three in the
male group and four in the female group, including two in common
for both genders.
Regarding the allelic analyses performed in the male patients group,
signiﬁcant results were found associated with a decrease in AO for the
A allele (Po0.001) of rs17217069 and the G allele (P= 0.002) of
rs2361634, and this variation correspond to 10 and 9 years, respec-
tively (Table 2).
In addition, in the female group, the CT genotype (Po0.001) of
rs5919392, the GA genotype (P= 0.001) of rs2361634 and the AT
genotype (P= 0.033) of rs5965433 were signiﬁcantly associated with
an earlier AO, and this variation correspond to 9 and 7 years for these
variants. On the other hand, the CT genotype (Po0.001) of rs5919393
was signiﬁcantly associated with a later AO (Table 2).
For rs5919393, in the male group the C allele (P= 0.015) was
associated with a decrease of 11 years, whereas in the female group this
SNP was associated with an increase in AO and the differences in
mean AO correspond to 7 years for the CT genotype (Table 2).
Concerning the HSD17B1 gene, none of the SNPs were found to be
signiﬁcantly associated with AO variation. In addition, we did not ﬁnd
any signiﬁcant interaction between AR and HSD17B1 genes.
No haplotypic effect was found for any of the genes studied (data
not shown).
Regarding parental transmission of the SNPs to the affected
children, we found a differential transmission for allele T of
rs28383573 in the APCS gene. We found that nonaffected fathers
transmitted more often than expected this allele that is involved in a
later onset.
Regarding AR gene, for rs5919392, we found that the affected
mothers transmitted more often than expected the T allele that is
associated with an early onset. For the other SNPs we did not ﬁnd any
signiﬁcant differences in parental transmission.
A bioinformatic’s analysis using FuncPred was also performed to
assess the functional impact of the SNPs associated with AO variation
of FAP ATTRV30M. This analysis predicted that one SNP in LD with
rs5919393 (rs2473881) may alter transcription factor binding (TFB)
sites in the AR gene, with a higher number of TFB sites when the A
allele was present.
DISCUSSION
Mechanisms responsible for AO variation in FAP ATTRV30M are still
elusive. Similar to several other neurodegenerative disorders, the TTR
gene point mutation alone does not fully determine the AO variation
or the course of the disease. Therefore, we have applied, for the ﬁrst
time, a family-centered approach also used in studies of other
Table 2 Signiﬁcant results of the analysis of APCS, RBP4 and AR SNPs and AO variation taking into account intrafamilial nonindependency
Gene SNP Genotypes B 95% CI P-value
APCS GG (reference) − − −
rs28383573 TTa 26.17 (23.08; 29.25) Po0.001
RBP4 CC (reference) − − −
rs7094671 TT 18.95 (4.10; 33.80) 0.012
CT 10.42 (2.38; 18.46) 0.011
rs11187545 TT (reference) − − −
CCa −28.49 (−44.56; −12.42) 0.001
CT −8.98 (−17.06; 16.67) 0.035
AR (male group) T (reference) − − −
rs5919393 C −10.59 (−19.14; −2.04) 0.015
G (reference) − − −
rs17217069 A −10.38 (−14.22; −6.54) Po0.001
A (reference) − − −
rs2361634 G −8.88 (−14.45; −3.31) 0.002
AR (female group) CC (reference) − − −
rs5919392 CT −8.53 (−12.76; −4.30) Po0.001
TT (reference) − − −
rs5919393 CT 6.63 (3.38; 9.87) Po0.001
AA (reference) − − −
rs2361634 GA −6.96 (−11.00; −2.92) 0.001
AA (reference) − − −
rs5965433 AT −6.76 (−12.97; −0.56) 0.033
B, unstandardized coefﬁcient (estimated quantitative effect of each genotype on AO variation compared with the reference genotype); CI, conﬁdence interval; P-value, signiﬁcance level was set
to 0.05.
aBased in only one individual with this genotype.
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diseases19,23 and focused on modiﬁer genes related with (1) TTR
functional pathways involved in pathophysiological processes related
to FAP ATTRV30M pathogenesis and also (2) sex-linked genes
because of observed differences between genders and parent-of-
origin effects associated with AO variation.
In a previous study, Soares et al9 analyzed ﬁve SNPs (also studied
by us) in a Portuguese sample of 92 patients and 85 controls using a
classic case–control approach. Thus, for APCS gene the authors
obtained signiﬁcant results for the combination of rs6689429 and
the rs2808661 genotypes associated with early onset when the early-
onset group versus controls was compared; in addition, a joint effect of
one SNP of the APCS gene (rs6689429) and two of the RBP4 gene
(rs7091052 and rs28383574) was associated with a later onset when
the late-onset group versus controls was compared. In addition, in the
study performed by Dardiotis et al8 that analyzed only one SNP
(rs2808661) of the APCS gene, also studied by us, the results were
quite different as no signiﬁcant modiﬁer effect was found. We did not
ﬁnd any signiﬁcant results for these SNPs, showing that different
approaches can lead to different results. Different genetic risk factors
can also be involved in different populations as in the case of the
Cypriot sample. Furthermore, the sample size was quite small when
compared with ours, showing that a larger sample, increasing the
statistical power, is needed to draw some conclusion.
The role of rs28383573 in the APCS gene
Unlike other studies, we found in our sample a putative evidence of an
association with a later onset for the APCS gene. However, it should be
noted that the TT genotype (rare homozygous) of the rs28383573 only
appears once in our sample. This is in accordance with the observed
genotype frequencies in the European population (TT= 0.013), and
therefore we think that this result is worth mentioning. Although one
may question whether the effect found in this one individual is
sufﬁcient to associate this gene with AO, we look to this result as a
hypothesis to be further explored because of the differential parent
transmission effect found and the role of rare variants as genetic
modiﬁers.
APCS has been associated with several amyloid deposits and it has
been suggested that it stabilizes amyloid ﬁbrils, protecting them from
proteolytic degradation.11 A study performed in vitro using Drosophila
model showed that APCS binds to early TTR aggregates that are toxic
to neuronal cells, therefore acting as a protective factor in inhibition of
TTR-induced toxicity.24 Therefore, this protective role of APCS could
be increased by the presence of this variant, increasing the inhibition
of TTR toxicity and preventing an earlier AO.
RBP4 gene variants associated with different AO patterns
One SNP (rs7094671) of the RBP4 gene was associated with a late AO.
In addition, rs11187545 was associated with an early AO.
As with rs28383573 of APCS gene, the CC genotype of the RBP4
rs11187545 also appeared only once in our families but the CC
genotype frequency of this SNP is also low (CC= 0.003) in the
European population. As we found a signiﬁcant result for the CT
genotype, we consider that we cannot exclude the result for the CC
genotype because it strengthens the involvement of the C allele of the
rs11187545 in AO variability. RBP4 and TTR variants cause either
RNA or protein instability and result in abnormally low retinol
levels.25 Therefore, the lack of RBP4 or TTR alters the retinol levels
and increases urinary excretion of RBP4–retinol complex.26,27 The
presence of these variants could therefore alter RBP4–TTR binding,
preventing or increasing their binding to retinol, allowing us to
hypothesize that the protective role of RBP4 could be decreased
because of damaged TTR stability increasing aggregates formation,
leading to an earlier AO.
AR gene and AO variability
The anticipation effect in FAP ATTRV30M as a mechanism associated
with patients’ gender has already been previously described6 and has
reinforced the hypothesis that sex steroid hormone genes may also
have a modiﬁer role in the disease onset with the differences in AO
between males and females.
Importantly, we found that rs5919393 was associated with an earlier
onset in males and a later onset in females, leading us to suggest that
this variant can have a possible protector effect in females. AR acts as a
DNA-binding transcription factor that regulates positively or nega-
tively gene expression.28 From the in silico analysis we found that the A
allele of the rs2473881, which is in LD with rs5919393, may alter TFB
sites, promoting upregulation of this gene in the female late-onset
group. Furthermore, the rs2361634 is associated with an earlier onset
in both males and females, and we hypothesize that this variant could
be a genetic risk factor to both genders. Interestingly, we found a
differential parental transmission regarding rs5919392, showing that
affected mothers add a risk genetic effect to AO variation. These
differences in AO variation could also be partially explained by
different androgen levels in circulation in males and females as males
have higher androgen levels than females,29 and this can induce TTR
expression. Thus, as men have higher testosterone levels, increased
levels of TTR will be produced possibly leading to early TTR amyloid
deposits. Importantly, and conﬁrming these observations, lower levels
of TTR were found in women.30 In a study using a mouse model with
Alzheimer’s disease it was shown that a decrease or absence of TTR
inﬂuences the levels of sex hormones with a gender effect.31 A positive
association between sex hormones and TTR levels were found in other
studies.32,33 In addition, testosterone showed to have a neuroprotective
role in animal studies,34,35 and some studies have shown protective
actions of sex hormones in several neurodegenerative diseases.36
Regarding the HSD17B1 gene, although we did not found an effect
in AO variation, this does not exclude other variants in other estradiol-
linked genes as possible modiﬁer candidate genes in FAP ATTRV30M.
All the results found seem to be due to the main effects of each
gene, as no interaction between genes was observed.
Our study has several strengths: a large sample size for a rare disease
and a family-centered approach that prevents population stratiﬁcation,
unlike a case–control study.28 GEE analysis is also appropriate, as it
corrects for familial correlations of AO and it tends to have a greater
power to detect a statistically signiﬁcant effect than other similar
methods.37 We also paid a special attention to statistical analysis by
including multiple testing corrections.
However, further investigation around AO variability in FAP
ATTRV30M is necessary to deepen our results and provide more
insight into the underlying mechanisms involved. In addition, func-
tional studies will also be required in the near future to conﬁrm these
results. The present study included only Portuguese patients, and thus
replication of this approach in other populations would be very
interesting.
Our ﬁndings conﬁrmed the involvement of APCS and RBP4 genes
in the AO variation in FAP and this is the ﬁrst study that unravels a
new modiﬁer gene – AR gene – as a potential modulator of AO
variation in FAP ATTRV30M, particularly, sex linked. In conclusion,
these ﬁndings may have important implications in genetic counseling
of offspring and in the follow-up of mutation carriers.
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